Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 3Sarcoma 2Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Carcinoma 1Adenoma 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Sunitinib × Endocrine × Clear all
NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Pfizer

Phase 4 Completed
106 enrolled 26 charts
EndocrineGastrointestinalNET

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡